Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients

• Published in: Antimicrobial agents and chemotherapy Vol. 65; no. 9; p. e0260620
• Main Authors: Trang, M., Griffith, D. C., Bhavnani, S. M., Loutit, J. S., Dudley, M. N., Ambrose, P. G., Rubino, C. M.
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 17.08.2021
• Subjects: Anti-Bacterial Agents - therapeutic use; Boronic Acids; Drug Combinations; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Pharmacology; meropenem; vaborbactam; population pharmacokinetics

Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated p...